PriceTargets.com logo

Curaleaf - CURLF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.72
  • Forecasted Upside: 205.66%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$3.84 As of 02/7/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for CURLF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Curaleaf Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CURLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CURLF

Analyst Price Target is $11.72
▲ +205.66% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Curaleaf in the last 3 months. The average price target is $11.72, with a high forecast of $15.00 and a low forecast of $8.50. The average price target represents a 205.66% upside from the last price of $3.84.

This chart shows the closing price for CURLF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Curaleaf. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/25/2023Atb Cap MarketsReiterated RatingOutperform
12/30/2022Cantor FitzgeraldLower TargetOverweight$13.00 ➝ $12.00
12/1/2022WedbushInitiated CoverageOutperform$8.50
11/8/2022Stifel NicolausLower TargetC$9.50 ➝ C$8.50
11/8/2022Cantor FitzgeraldLower TargetOverweight$13.50 ➝ $13.00
10/31/2022Seaport Res PtnReiterated RatingBuy
10/28/2022Cantor FitzgeraldLower TargetOverweight$13.70 ➝ $13.50
10/28/2022BTIG ResearchReiterated RatingBuy
10/26/2022Roth CapitalReiterated RatingBuy
8/9/2022Canaccord Genuity GroupLower TargetC$14.50 ➝ C$13.50
8/9/2022Alliance Global PartnersLower TargetC$15.00 ➝ C$12.00
8/9/2022CowenLower Target$25.00 ➝ $10.00
5/10/2022Canaccord Genuity GroupLower TargetC$15.50 ➝ C$14.50
5/10/2022Stifel NicolausLower TargetC$25.00 ➝ C$24.00
5/10/2022MKM PartnersReiterated RatingBuy$14.00
4/25/2022Cantor FitzgeraldBoost TargetOverweight$15.50 ➝ $16.50
3/7/2022Stifel NicolausLower TargetC$31.00 ➝ C$25.00
3/4/2022Cantor FitzgeraldLower TargetOverweight$16.50 ➝ $15.50
3/4/2022Needham & Company LLCLower TargetBuy$17.00 ➝ $15.00
2/25/2022BenchmarkInitiated CoverageBuy$12.00
1/7/2022Wolfe ResearchInitiated CoveragePeer Perform
1/4/2022Cantor FitzgeraldLower TargetOverweight$18.50 ➝ $16.50
11/9/2021Roth CapitalLower TargetBuy$19.00 ➝ $16.00
11/9/2021Stifel NicolausLower TargetBuyC$33.00 ➝ C$31.00
11/9/2021Alliance Global PartnersLower TargetBuyC$29.00 ➝ C$23.00
11/9/2021Craig HallumDowngradeBuy ➝ Hold
11/8/2021Craig HallumLower TargetAverage ➝ Buy$21.00 ➝ $16.00
11/3/2021Cantor FitzgeraldLower TargetOverweight$24.00 ➝ $20.00
11/1/2021Stifel NicolausBoost TargetBuyC$32.25 ➝ C$33.00
10/8/2021Needham & Company LLCLower TargetBuy$19.75 ➝ $19.00
8/10/2021Needham & Company LLCInitiated CoverageBuy$19.75
8/3/2021Needham & Company LLCReiterated RatingBuy$19.75
7/7/2021Jefferies Financial GroupInitiated CoverageBuy$32.00
3/10/2021Cantor FitzgeraldBoost TargetOverweight$23.50 ➝ $26.50
3/10/2021Needham & Company LLCBoost TargetBuy$18.50 ➝ $19.75
3/8/2021BTIG ResearchInitiated CoverageBuy
2/25/2021Stifel NicolausBoost TargetBuy$23.00 ➝ $32.25
1/20/2021Roth CapitalBoost TargetBuy$14.00 ➝ $20.00
1/20/2021Cantor FitzgeraldBoost TargetOverweight$20.00 ➝ $23.50
1/19/2021Needham & Company LLCBoost TargetBuy$14.00 ➝ $18.50
12/3/2020Craig HallumInitiated CoverageBuy$19.00
11/18/2020Needham & Company LLCBoost TargetBuy$13.50 ➝ $14.00
11/18/2020Cantor FitzgeraldBoost TargetOverweight$18.00 ➝ $20.00
8/18/2020Alliance Global PartnersBoost TargetBuy$14.00 ➝ $16.00
8/18/2020Needham & Company LLCBoost TargetBuy$11.00 ➝ $13.50
8/18/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$18.00
8/6/2020Needham & Company LLCBoost TargetBuy$10.70 ➝ $11.00
8/4/2020Cantor FitzgeraldBoost TargetNeutral$7.50 ➝ $10.00
7/23/2020Alliance Global PartnersBoost TargetBuy$12.00 ➝ $14.00
7/22/2020Stifel NicolausInitiated CoverageBuy
6/22/2020Needham & Company LLCReiterated RatingBuy$10.70
6/8/2020Roth CapitalInitiated CoverageBuy$9.00
5/19/2020Cantor FitzgeraldBoost TargetNeutral$6.00 ➝ $7.50
5/19/2020Needham & Company LLCBoost TargetBuy$5.90 ➝ $10.10
5/12/2020Needham & Company LLCBoost TargetBuy$5.50 ➝ $5.90
3/25/2020Cantor FitzgeraldBoost TargetNeutral$4.10 ➝ $4.70
3/17/2020Needham & Company LLCLower TargetBuy$8.80 ➝ $5.50
2/13/2020Cantor FitzgeraldInitiated CoverageNeutral$8.60
2/11/2020Alliance Global PartnersInitiated CoverageBuy
12/23/2019Needham & Company LLCReiterated RatingBuy$7.25
12/3/2019Needham & Company LLCInitiated CoverageBuy$7.25
11/6/2019MKM PartnersUpgradeSell ➝ Neutral
9/20/2019MKM PartnersInitiated CoverageSell$5.00
9/13/2019CowenInitiated CoverageOutperform$11.00
6/10/2019Compass PointInitiated CoverageBuy
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
7/12/2022
  • 9 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/10/2022
  • 11 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 4 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Curaleaf logo
Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Cannabis Operations and Non-Cannabis Operations segments. The Cannabis Operations segment includes the production and sale of cannabis via retail and wholesale channels. The Non-Cannabis Operations segment provides professional services including cultivation, processing and retail know-how and back office administration, intellectual property licensing, real estate leasing services and lending facilities to medical and adult-use cannabis licensees under management service agreements. The company was founded on November 13, 2014 and is headquartered in Wakefield, MA.
Read More

Today's Range

Now: $3.84
Low: $3.72
High: $3.86

50 Day Range

MA: $4.48
Low: $3.59
High: $7.57

52 Week Range

Now: $3.84
Low: $3.31
High: $9.28

Volume

257,409 shs

Average Volume

440,084 shs

Market Capitalization

$2.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Curaleaf?

The following equities research analysts have issued research reports on Curaleaf in the last year: Alliance Global Partners, Atb Cap Markets, Benchmark Co., BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, MKM Partners, Needham & Company LLC, Roth Capital, Seaport Res Ptn, Stifel Nicolaus, and Wedbush.
View the latest analyst ratings for CURLF.

What is the current price target for Curaleaf?

9 Wall Street analysts have set twelve-month price targets for Curaleaf in the last year. Their average twelve-month price target is $11.72, suggesting a possible upside of 205.7%. Needham & Company LLC has the highest price target set, predicting CURLF will reach $15.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $8.50 for Curaleaf in the next year.
View the latest price targets for CURLF.

What is the current consensus analyst rating for Curaleaf?

Curaleaf currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CURLF will outperform the market and that investors should add to their positions of Curaleaf.
View the latest ratings for CURLF.

What other companies compete with Curaleaf?

Other companies that are similar to Curaleaf include Ozon, Sonos, Weber, ProSiebenSat.1 Media and Flight Centre Travel Group. Learn More about companies similar to Curaleaf.

How do I contact Curaleaf's investor relations team?

Curaleaf's physical mailing address is 301 Edgewater Place, Wakefield, MA 01880. The company's listed phone number is (781) 451-0150 and its investor relations email address is [email protected] The official website for Curaleaf is www.curaleaf.com. Learn More about contacing Curaleaf investor relations.